Myoclonic Epilepsy in Infancy: Disease-Characteristics Report

Executive summary and scope

Myoclonic epilepsy in infancy (MEI) is a rare, usually self-limited generalized epilepsy syndrome beginning in an otherwise normally developing infant. Its defining events are brief generalized myoclonic seizures, particularly of the head and upper limbs, occurring repeatedly in wakefulness and sleep. The most authoritative current definition is the International League Against Epilepsy (ILAE) 2022 position statement on neonatal- and infant-onset epilepsy syndromes, published May 2022 (DOI: https://doi.org/10.1111/epi.17239). (zuberi2022ilaeclassificationand pages 12-14)

A critical terminology warning is required: MEI is not Dravet syndrome, whose historical name was “severe myoclonic epilepsy in infancy” (SMEI). Dravet syndrome is a developmental and epileptic encephalopathy, usually associated with SCN1A, prolonged febrile or afebrile hemiclonic/generalized convulsive seizures, pharmacoresistance, and developmental impairment. MEI must also not be merged with familial infantile myoclonic epilepsy, a separately indexed genetic entity associated in disease databases with genes including TBC1D24, SCN8A, CPLX1, and KIF5A. Open Targets gives classic MEI as MONDO_0100566 but reports no established disease–target association for that entity. (OpenTargets Search: myoclonic epilepsy in infancy, zuberi2022ilaeclassificationand pages 12-14)

Table: This table compiles ontology-ready, knowledge-base-focused evidence for classic Myoclonic Epilepsy in Infancy, centered on the 2022 ILAE definition and supporting review data. It highlights key diagnostic and prognostic facts while explicitly separating MEI from Dravet syndrome and familial infantile myoclonic epilepsy.

1. Disease information

Definition and classification

MEI is an electroclinical syndrome—an age-dependent cluster of seizure and EEG features—rather than a disease currently defined by a single molecular lesion. The ILAE places it among epilepsy syndromes beginning in neonates and infants and describes a self-limited course in most affected children. Data are aggregated from syndrome-level clinical cohorts, specialty-center series, population-based epilepsy cohorts, and expert consensus; they are not individual-patient EHR data in this report. (zuberi2022ilaeclassificationand pages 12-14)

Preferred name: Myoclonic epilepsy in infancy.
Common synonyms: myoclonic epilepsy of infancy; benign myoclonic epilepsy in infancy; benign myoclonic epilepsy of infancy. “Benign” is now generally avoided because 15–37% of reported patients do not have completely normal long-term neurodevelopment and approximately 10% later develop another epilepsy. The reflex-predominant phenotype may be called reflex myoclonic epilepsy in infancy. (zuberi2022ilaeclassificationand pages 14-16, zuberi2022ilaeclassificationand pages 12-14)

Identifiers:

• MONDO: MONDO:0100566, myoclonic epilepsy in infancy. (OpenTargets Search: myoclonic epilepsy in infancy)
• EFO: EFO:0700105, myoclonic epilepsy of infancy, as returned by Open Targets. (OpenTargets Search: myoclonic epilepsy in infancy)
• OMIM/Orphanet: no confidently verified disease-specific identifier was recovered for classic sporadic MEI; do not substitute identifiers for familial infantile myoclonic epilepsy or Dravet syndrome.
• ICD-10/ICD-11: coding is generally under epilepsy/generalized epilepsy categories; a uniquely validated MEI-specific billable code was not established in the retrieved evidence.
• MeSH: use the broader epilepsy/myoclonic epilepsy concepts; no uniquely verified MEI descriptor was identified.

2. Etiology, risk, and protective factors

The cause of classic MEI remains unresolved. Approximately 10% have a family history of epilepsy or febrile seizures, supporting genetic susceptibility, but the ILAE review states that no causal gene has been identified for the classic syndrome. Therefore, SCN1A, SLC2A1, YWHAG, TBC1D24, or other epilepsy genes should not be annotated as established MEI causes without evidence that the individual satisfies classic ILAE MEI criteria and that competing etiology-specific syndromes have been excluded. (zuberi2022ilaeclassificationand pages 14-16, bayat2021epilepsysyndromesin pages 6-8)

No reproducible susceptibility locus, modifier gene, protective allele, epigenetic signature, or chromosomal abnormality is established. The relevant inheritance model is consequently unknown/complex, not proven autosomal dominant or recessive. Penetrance, carrier frequency, anticipation, founder effects, and germline-mosaicism rates cannot presently be assigned.

No toxin, pollutant, occupation, diet, infection, vaccination, smoking exposure, or other lifestyle factor is established as a cause. Sudden sound, touch, startle, and occasionally intermittent photic stimulation can precipitate individual seizures but are reflex triggers, not causes of the underlying epilepsy. Febrile seizures occur in up to one-third and may precede or follow the myoclonic seizures, but fever should not be interpreted as a demonstrated etiologic exposure. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

No validated genetic or environmental protective factor, formal gene–environment interaction, or primary prevention strategy is known.

3. Phenotypes

Core seizure phenotype

The mandatory clinical phenotype is frequent brief myoclonic seizures involving the head and upper arms/upper limbs, commonly producing head nods, shoulder or arm jerks, or brief loss of hand control. Events occur several or multiple times daily, in both wakefulness and sleep. Consciousness is usually preserved or only too briefly affected to assess. Approximately one-third of patients have reflex events induced by noise, touch, or startle. (zuberi2022ilaeclassificationand pages 12-14, bayat2021epilepsysyndromesin pages 6-8)

Suggested terms include generalized myoclonic seizure (HPO HP:0002123), infantile onset (HP:0003593), febrile seizures (HP:0002376) when present, and an appropriate reflex/startle-induced seizure term when supported by the record. Because ontology labels evolve, identifiers should be checked against the production HPO release before ingestion.

EEG phenotype

The awake background is typically normal. Interictal EEG demonstrates generalized spike-wave or polyspike-wave discharges, commonly more evident in early sleep. The electroclinical discharge is often described at approximately 3 Hz. A sleep recording is therefore important. If interictal sleep EEG does not show generalized spike-wave, ictal video-EEG is strongly recommended to distinguish epileptic myoclonus from nonepileptic infantile myoclonus, hyperekplexia, or physiological hypnic jerks. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

Suggested annotations are abnormal EEG (HP:0010848) and generalized spike-wave/polyspike-wave descriptors. The ictal event and EEG correlate should be represented separately where the data model permits.

Development, behavior, and examination

Development before seizure onset and neurological examination are ordinarily normal. Long-term development is reported as normal in 63–85%. A minority develops mild intellectual disability, learning difficulties, or attention problems; moderate-to-severe intellectual disability is rare and is not necessarily proportional to seizure frequency. Relevant conditional terms include intellectual disability (HP:0001249), global developmental delay (HP:0001263), learning disability, and attention deficit. (zuberi2022ilaeclassificationand pages 12-14)

Other clinical findings

Febrile seizures occur in up to one-third. At onset, absence, atonic, focal, clonic, generalized tonic-clonic seizures, or epileptic spasms are exclusionary for classic MEI. Falls, persistent focal deficits, dysmorphism, movement disorder, regression, and systemic laboratory abnormalities are not defining features and should prompt reassessment. (zuberi2022ilaeclassificationand pages 12-14)

Quality of life

No MEI-specific EQ-5D, SF-36, PROMIS, or validated caregiver quality-of-life statistics were identified. During the active phase, multiple daily jerks can impair feeding, object handling, sleep, safety, and caregiver confidence. Later learning or attention problems may affect school functioning even after seizure remission, which helps explain why “benign” is an imperfect label. These functional effects are clinically plausible but are not quantified in the available syndrome literature.

4. Genetic and molecular information

There is presently no validated causal gene, recurrent pathogenic variant, HGNC-defined gene set, allele frequency, or established loss-/gain-of-function mechanism for classic MEI. Consequently, no variant should be classified as “pathogenic for MEI” solely because it occurs in a person with infantile myoclonus. Molecular findings must be interpreted under ACMG/AMP criteria and against the gene-specific phenotype.

The database distinction is especially important: Open Targets links familial infantile myoclonic epilepsy (MONDO:0011506) to TBC1D24, SCN8A, CPLX1, and KIF5A, while its classic MEI record has no associated targets. These associations cannot be transferred across disease records. (OpenTargets Search: myoclonic epilepsy in infancy)

No established modifier gene, DNA-methylation signature, histone abnormality, pathogenic copy-number change, or recurrent chromosomal rearrangement has been demonstrated. Reports of gene-positive MEI-like phenotypes should be represented as gene-associated epilepsy with an MEI-like presentation pending replication and nosological validation.

5. Environmental information

No causal environmental exposure or infectious agent has been identified. Sound, tactile stimulation, startle, and occasionally light stimulation activate susceptible seizure networks in reflex MEI. Practical stimulus management may reduce provoked events, but excessive avoidance can adversely affect normal infant development and is not disease-modifying. There is no evidence that diet, exercise, alcohol, tobacco, pollution, radiation, or occupational exposure has a disease-specific role in infants with classic MEI. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

6. Mechanism and pathophysiology

Current mechanistic model

The best-supported causal chain is electroclinical rather than molecular:

1. An unknown, probably developmentally regulated susceptibility alters excitability in bilateral generalized cortical–subcortical networks.
2. Sleep-state transitions or abrupt sensory input can synchronize these networks.
3. Generalized spike-/polyspike-wave activity recruits bilateral motor cortex and descending motor pathways.
4. Brief synchronous muscle activation produces head and upper-limb myoclonus.
5. Maturation and/or antiseizure treatment reduces network susceptibility, accounting for remission in nearly all cases.

Steps 1 and 5 remain hypotheses; no MEI-specific channel, receptor, transmitter, inflammatory, metabolic, or mTOR/PI3K-AKT pathway defect is established. The normal neurological examination, normal awake background, and nonlesional MRI support functional network dysregulation rather than progressive tissue destruction. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

Suggested broad GO annotations, to be used as mechanistic hypotheses rather than demonstrated disease mechanisms, include regulation of membrane potential (GO:0042391), synaptic signaling (GO:0099536), regulation of neuronal action potential, and synchronization of neuronal activity. Candidate cell types include excitatory and inhibitory neurons—glutamatergic neuron (CL:0000679) and GABAergic neuron (CL:0000617)—but no MEI-specific cellular pathology has been shown.

No disease-specific transcriptomic, single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, CRISPR-screen, or multi-omics result was identified. There is likewise no established immune activation, oxidative injury, neurodegeneration, apoptosis, autophagy defect, enzyme deficiency, or tissue-damage mechanism.

7. Anatomical structures affected

The clinically affected organ is the central nervous system, particularly bilateral brain networks generating generalized epileptiform activity and motor output. Suggested anatomical annotations are brain (UBERON:0000955), cerebral cortex (UBERON:0000956), and possibly thalamus/generalized thalamocortical network as a systems-level inference. There is no consistent focal lesion, lateralization, or secondary organ involvement. (zuberi2022ilaeclassificationand pages 14-16)

At subcellular level, neuronal plasma membrane, axon, synapse, and postsynaptic membrane are biologically plausible compartments, but none is specifically proven. A normal/nonlesional MRI is expected; a causal structural lesion argues against classic MEI.

8. Temporal development

Onset is usually 4 months to 3 years, peaking at 6–18 months. Onset at or before 4 months or after 3 years is an alert against the classic diagnosis. The beginning may be abrupt from the caregiver’s perspective, but the course is episodic, with multiple daily seizures during the active phase. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

Myoclonic seizures remit in nearly all patients within 6 months to 5 years after onset. Most ultimately discontinue antiseizure medication. Approximately 10% develop another epilepsy in later childhood or adolescence, most often juvenile myoclonic epilepsy. Developmental surveillance should therefore continue after seizure remission. (bayat2021epilepsysyndromesin pages 6-8, zuberi2022ilaeclassificationand pages 12-14)

There are no validated early/intermediate/advanced stages. The useful clinical phases are active infantile myoclonus, seizure remission, medication withdrawal where appropriate, and longer-term monitoring for learning/attention difficulties or later generalized epilepsy.

9. Inheritance and population

MEI constitutes <0.8% of children with epilepsy seen in specialty centers and approximately 1.1% of epilepsies beginning before 36 months in the population-based evidence summarized by ILAE. Male predominance is approximately 2:1. These figures do not provide robust prevalence per 100,000 or annual incidence estimates, and geographic or ancestry-specific differences have not been established. (zuberi2022ilaeclassificationand pages 12-14)

Family history of epilepsy or febrile seizures occurs in about 10%, but Mendelian inheritance, penetrance, expressivity, carrier frequency, anticipation, founder effects, and consanguinity effects remain undefined. (zuberi2022ilaeclassificationand pages 14-16, bayat2021epilepsysyndromesin pages 6-8)

10. Diagnostics

Clinical and electrophysiological diagnosis

Diagnosis rests on the age-dependent electroclinical pattern:

• onset between 4 months and 3 years;
• normal pre-onset development and neurological examination;
• multiple daily generalized myoclonic seizures of head/upper limbs in wakefulness and sleep;
• generalized spike-wave or polyspike-wave, especially in sleep;
• no causal structural lesion;
• no competing seizure types at onset. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

Video-EEG including sleep is the key test. Ictal recording is particularly valuable if habitual jerks have no clear interictal correlate. Brain MRI is expected to be nonlesional; MRI is appropriate when there are focal findings, atypical development, abnormal examination, or an atypical EEG. Routine blood chemistry, metabolic studies, CSF, biopsy, PET, EMG, ECG, or other biomarkers are not diagnostic for classic MEI and should be guided by atypical features.

Genetic testing

Genetic testing is not required to confirm a textbook MEI phenotype because no causal gene is established. Nevertheless, an infantile epilepsy panel or exome/genome sequencing is reasonable when there is developmental delay/regression, dysmorphism, drug resistance, focal or multiple seizure types, abnormal MRI, very early onset, a strong family history, or failure to meet ILAE criteria. Such testing primarily detects alternative etiologies, not classic MEI. Broad early-onset epilepsy literature supports panels, exomes, or genomes because they can identify actionable phenocopies, but this evidence is not an MEI-specific diagnostic-yield estimate. (bayat2021epilepsysyndromesin pages 6-8)

CMA is appropriate when developmental or congenital abnormalities suggest a copy-number disorder. Karyotype, FISH, mitochondrial DNA, RNA sequencing, and repeat-expansion testing are not routine MEI tests unless another phenotype indicates them.

Differential diagnosis

• Benign myoclonus of early infancy: similar jerks but no epileptiform ictal EEG.
• Hyperekplexia: exaggerated pathological startle, often with stiffness, without generalized epileptic EEG correlate.
• Hypnic jerks: physiological sleep-onset myoclonus without epileptic correlate.
• Dravet syndrome: usually prolonged febrile/afebrile hemiclonic or generalized convulsive seizures beginning in the first year, later multiple seizure types, developmental slowing, and frequent SCN1A pathogenic variants.
• Epilepsy with myoclonic-atonic seizures: later polymorphic generalized epilepsy with myoclonic-atonic/drop seizures.
• Infantile epileptic spasms syndrome: clusters of spasms, developmental concerns, and hypsarrhythmia or related EEG pattern.
• Early myoclonic encephalopathy/DEE: neonatal or very early onset, abnormal development/examination, severe EEG abnormality, and poor course.
• Focal structural epilepsy: focal semiology/EEG or causal MRI lesion. (zuberi2022ilaeclassificationand pages 12-14, zuberi2022ilaeclassificationand pages 14-16)

There is no population or newborn screening program for MEI. Screening asymptomatic relatives is not supported because no validated causal gene exists.

11. Outcome and prognosis

Seizure prognosis is excellent: nearly all patients remit over 6 months to 5 years, and most eventually stop medication. Long-term neurodevelopment is normal in 63–85%, but mild intellectual, learning, or attention problems occur in a clinically important minority. Approximately 10% later develop another epilepsy. (zuberi2022ilaeclassificationand pages 12-14)

No MEI-specific 5- or 10-year survival rate, excess mortality rate, SUDEP estimate, or reduction in life expectancy was identified. Current evidence does not characterize classic MEI as a progressive or lethal disorder. Prognostically adverse signals include atypical onset age, abnormal development or examination, additional seizure types, focal EEG/MRI abnormalities, persistent drug resistance, or failure of expected remission; these features should trigger diagnostic reconsideration rather than automatically being labeled severe MEI.

No validated molecular prognostic biomarker or disease-specific quality-of-life instrument exists.

12. Treatment

Pharmacotherapy and strategy

Evidence consists mainly of observational series and expert practice rather than modern randomized MEI trials. A broad-spectrum antiseizure medication is used when seizures are frequent, disruptive, or diagnostically secure. Historical and review-based practice most commonly favors valproate as first-line monotherapy for generalized myoclonus; levetiracetam, clonazepam, or topiramate may be considered when valproate is unsuitable or ineffective. These alternatives have substantially weaker MEI-specific evidence. The ILAE evidence establishes that most patients ultimately discontinue therapy after remission but does not provide comparative response rates. (zuberi2022ilaeclassificationand pages 12-14)

Suggested NCIT-level intervention concepts are anticonvulsant therapy, valproic acid, levetiracetam, clonazepam, and topiramate; exact NCIT identifiers should be verified against the current release. Medication selection and withdrawal should be supervised by a pediatric neurologist. Valproate requires age-appropriate counseling and monitoring for hepatic toxicity, pancreatitis, thrombocytopenia, hyperammonemia, weight/metabolic effects, and future reproductive risk. Benzodiazepines may cause sedation or tolerance; levetiracetam may cause behavioral adverse effects; topiramate can impair appetite, cognition, acid-base balance, and renal-stone risk.

A practical algorithm is: confirm epileptic myoclonus with video-EEG including sleep; treat frequent events with a broad-spectrum ASM; reassess seizure and developmental response; investigate phenocopies if resistant or atypical; and consider gradual withdrawal after sustained electroclinical remission. There is no evidence for epilepsy surgery because MEI is generalized and nonlesional. Ketogenic diet, vagus-nerve stimulation, immunotherapy, or other interventions are not routine for classic MEI; needing them should prompt reconsideration of the diagnosis.

Advanced and experimental therapy

No MEI-specific gene therapy, ASO, siRNA, mRNA, cell therapy, CRISPR therapy, targeted small molecule, immunotherapy, or interventional clinical trial was identified. Trials retrieved for SCN1A-Dravet syndrome—including zorevunersen/STK-001 studies—are not MEI trials and should not populate the MEI treatment record.

Supportive care includes seizure first-aid education, individualized safety advice, developmental and school surveillance, and speech, occupational, behavioral, or educational intervention when deficits are detected.

13. Prevention

Primary prevention is unavailable because the cause is unknown. Vaccination is not a disease-specific preventive intervention and routine immunization should follow standard pediatric recommendations. Avoidance of known abrupt sensory triggers may reduce individual reflex seizures but does not prevent MEI and should be balanced against normal development.

Secondary prevention consists of prompt recognition, video-EEG confirmation, treatment when warranted, and avoidance of diagnostic delay. Tertiary prevention includes injury precautions, fever/seizure plans, monitoring treatment toxicity, developmental surveillance, and follow-up into adolescence for later generalized epilepsy. There is no validated carrier, prenatal, preimplantation, newborn, or cascade-screening program for classic MEI. Genetic counseling should emphasize uncertain etiology and avoid assigning a Mendelian recurrence risk without a specific molecular diagnosis.

14. Other species and natural disease

No naturally occurring veterinary disorder was identified as a validated species homolog of classic human MEI. Animal epilepsies involving myoclonus or orthologues such as Scn1a, Scn8a, or Tbc1d24 model other genetic epilepsies and must not automatically be labeled MEI. No zoonotic transmission or cross-species infectious susceptibility applies.

15. Model organisms

No validated disease-specific mouse, rat, zebrafish, Drosophila, C. elegans, organoid, iPSC, or cellular model of classic MEI was identified, consistent with the absence of a confirmed molecular cause. Generalized spike-wave and reflex-seizure models can test network excitability or antiseizure drugs, but they do not reproduce the complete age, seizure, EEG, remission, and developmental phenotype required for construct and face validity. Gene-specific models are appropriate only for the corresponding etiology-specific epilepsy or phenocopy.

Evidence appraisal and recent developments

The decisive modern development is the 2022 ILAE standardized syndrome definition, which provides epidemiology, mandatory criteria, alerts, exclusions, EEG expectations, imaging findings, and natural history. Its abstract defines an epilepsy syndrome as an electroclinical cluster and separates self-limited infantile syndromes from developmental and epileptic encephalopathies; this is the appropriate framework for MEI. Publication: May 2022; DOI URL: https://doi.org/10.1111/epi.17239. (zuberi2022ilaeclassificationand pages 12-14)

A 2021 genetics review states that comprehensive panels, exomes, and genomes have increased diagnostic yield in early-onset epilepsies and enabled precision medicine, while specifically noting that causal genes for MEI had not been identified. Its abstract states that “early genetic testing is a cornerstone” of precision strategies in monogenic epilepsies; for MEI, the principal present utility is finding an alternative molecular diagnosis. Publication: July 2021; DOI URL: https://doi.org/10.3390/genes12071051. (bayat2021epilepsysyndromesin pages 6-8)

No 2023–2024 primary study was found that overturns the 2022 ILAE understanding of classic MEI, establishes a causal gene, supplies population prevalence per 100,000, or demonstrates a disease-specific therapy. The most defensible current expert position is therefore conservative: diagnose MEI electroclinically, preserve strict separation from Dravet syndrome and familial infantile myoclonic epilepsy, use genetic testing for atypical presentations/phenocopies, and explicitly mark molecular, omics, prevention, model, and trial fields as unresolved.

References

1. (zuberi2022ilaeclassificationand pages 12-14): Sameer M. Zuberi, Elaine Wirrell, Elissa Yozawitz, Jo M. Wilmshurst, Nicola Specchio, Kate Riney, Ronit Pressler, Stephane Auvin, Pauline Samia, Edouard Hirsch, Santiago Galicchio, Chahnez Triki, O. Carter Snead, Samuel Wiebe, J. Helen Cross, Paolo Tinuper, Ingrid E. Scheffer, Emilio Perucca, Solomon L. Moshé, and Rima Nabbout. Ilae classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ilae task force on nosology and definitions. Epilepsia, 63:1349-1397, May 2022. URL: https://doi.org/10.1111/epi.17239, doi:10.1111/epi.17239. This article has 1122 citations and is from a domain leading peer-reviewed journal.

2. (OpenTargets Search: myoclonic epilepsy in infancy): Open Targets Query (myoclonic epilepsy in infancy, 24 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

3. (zuberi2022ilaeclassificationand pages 14-16): Sameer M. Zuberi, Elaine Wirrell, Elissa Yozawitz, Jo M. Wilmshurst, Nicola Specchio, Kate Riney, Ronit Pressler, Stephane Auvin, Pauline Samia, Edouard Hirsch, Santiago Galicchio, Chahnez Triki, O. Carter Snead, Samuel Wiebe, J. Helen Cross, Paolo Tinuper, Ingrid E. Scheffer, Emilio Perucca, Solomon L. Moshé, and Rima Nabbout. Ilae classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ilae task force on nosology and definitions. Epilepsia, 63:1349-1397, May 2022. URL: https://doi.org/10.1111/epi.17239, doi:10.1111/epi.17239. This article has 1122 citations and is from a domain leading peer-reviewed journal.

4. (bayat2021epilepsysyndromesin pages 6-8): Allan Bayat, Michael Bayat, Guido Rubboli, and Rikke S. Møller. Epilepsy syndromes in the first year of life and usefulness of genetic testing for precision therapy. Genes, 12:1051, Jul 2021. URL: https://doi.org/10.3390/genes12071051, doi:10.3390/genes12071051. This article has 119 citations.

Artifacts

• Edison artifact artifact-00